Merck closed up about 10.8% on Thursday and touched a 52-week high after the cancer-vaccine combination it co-developed with Moderna met its Phase 3 endpoints in resected melanoma, with no new safety signal across 1,137 patients.
The read-through the market cared about: it pushes the Keytruda franchise into earlier-stage disease and into a combination setting.
→ Why it moved: https://marketchacha.com/movers
This article is for educational and informational purposes only. It is not financial advice, investment recommendation, or a solicitation to buy or sell securities. Investing involves significant risks. I am not a SEBI-registered investment advisor. Readers should consult their own financial advisor and conduct their own research before making any investment decisions.
Comments
Join the conversation
Sign in to join the conversation.
Follow replies, add your view, and take part in the discussion.
Sign in to commentLoading comments...